Superfeet to Produce 30,000 Respirator Masks for Local Healthcare Workers and Hospitals

A week after a national announcement opening their doors to help those needing access to personal protective equipment (PPE) to combat the COVID-19 pandemic, Superfeet and sister company Flowbuilt Manufacturing have started production of PPE masks with 3D-printed elements.

It took less than a week for Superfeet employee-owners to mobilize their product development and operations departments to pivot from insole production to making life-saving equipment using their Ferndale 3D printing and manufacturing facilities. Approximately 30,000 of these PPE masks will be produced and distributed to hospitals in the Pacific Northwest immediately.

“We started conversations with local hospitals and healthcare workers last week and discovered a massive need for PPE, as demand has skyrocketed over the past few weeks,” says John Rauvola, CEO and President at Superfeet. “You can feel the pride our team of employee-owners takes in being able to create something tangible to help combat this pandemic and better protect our community’s first line of defense.”

When Superfeet opened their doors to help those needing access to PPE, they sent a call-to-action challenging their local community to get involved. Another Washington-based company, Pioneer Aerofab– a business focused on manufacturing airplane interiors – quickly joined the cause and is supplying the mask’s hood portion. Tim Williamson, Pioneer Aerofab’s Owner and CEO explains, “It’s easy to be overwhelmed by the sheer magnitude of COVID-19 and its effect on our daily lives and those around the world. Looking at how you can make an impact on a local level is the best place to start. That’s precisely what we did when we heard about Superfeet’s plan.”

Superfeet continues to offer their 3D printers and manufacturing capabilities to the effort to combat COVID-19.

Medical facilities in need of personal protective equipment can reach out to covidresponse@superfeet.com to see if Superfeet can be of assistance.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”